Biologix - Mitsubishi Tanabe Pharma GmbH Cooperation in the Middle East - North Africa region
Mitsubishi Tanabe Pharma GmbH and Biologix FZ LLC Partner to Distribute Radicava (edaravone) in the Middle East and North Africa Region.
Duesseldorf December, 21th 2020 -- Mitsubishi Tanabe Pharma GmbH, a Pharmaceutical company built on the promise of providing treatments for patients who have limited or inadequate therapeutic options has entered into an exclusive agreement with Biologix FZ LLC under which Biologix will distribute Radicava (edaravone) in certain countries throughout the Middle East and North African (MENA) region. Under the terms of the agreement, Biologix will be responsible for managing named-patient requests through which physicians can legally and ethically prescribe Radicava for patients prior to commercial availability.
Edaravone is a free-radical scavenger that was discovered by Mitsubishi Tanabe Pharma. It was approved by the Japanese Ministry of Health, Labour and Welfare in April 2001 as a treatment agent for the acute stage of cerebral infarction. In Japan, it is being marketed under the product name RADICUT®. Edaravone has the effect of scavenging free radicals that arise accompanying cerebral ischemia, controlling the lipid peroxidation reaction, and protecting neurons in the region of the ischemia and the surrounding region. Accordingly, it is thought that edaravone has the effect of scavenging free radicals, which increase in ALS, protecting motor neurons from oxidative stress, and delaying the decline in muscle strength and the progress of muscular atrophy.
For use as a treatment for ALS, edaravone was approved in Japan in June 2015, South Korea in December 2015, US in May 2017, Canada in October 2018, Switzerland in January 2019, China in July 2019 and Indonesia in July 2020.
Biologix, a privately owned pharmaceutical company organized and existing under the laws of the United Arab Emirates (UAE), was incorporated in the Dubai Airport Free Zone in September 2002 as a regional distributor and promoter of pharmaceutical specialties in the Middle East & North Africa (MENA) countries. Biologix provides end to end services from the pre-registration phase including named patient supply, medical and disease awareness activities, to registration, promotion, cold chain distribution, tender management, market access programs, pharmacovigilance and product safety, as well as the administration of risk management plans, on behalf of its partners.
About Mitsubishi Tanabe Pharma GmbH (MTPD)
Headquartered in Dusseldorf, Germany, Mitsubishi Tanabe Pharma GmbH has been founded in 2003 as a subsidiary of Mitsubishi Pharma Europe Ltd. (London/UK). The company in Switzerland, based in Zurich, focuses not only on Radicava®, but also on marketing the direct thrombin inhibitor, Argatra® (argatroban monohydrate).
The parent company of MTPD is Mitsubishi Tanabe Pharma Corporation (MTPC) which is headquartered in Osaka, Japan.